Health ❯ Pharmaceuticals ❯ Weight Loss

GLP-1 Drugs

Wegovy Ozempic Novo Nordisk Consumer Behavior Market Trends Cost and Accessibility Obesity Treatment Mounjaro and Zepbound Lobbying Retatrutide

GLP-1 Drugs Linked to Lower Addiction Risk and Harm in Large VA Study

Researchers say randomized trials should test whether the links are causal.

Lindt Data Shows GLP‑1 Households Buying More, Not Less, Chocolate in the U.S.

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

Weight-Loss Pills Could Trim Airline Fuel Costs, Jefferies Says

Strive Compounding Sues Lilly and Novo, Alleging Antitrust Push to Block Compounded GLP-1s

Costco Adds $499 Ozempic and Wegovy Offer Across U.S. Pharmacies

TikTok and Instagram Remove Posts Promoting Counterfeit Retatrutide as Warnings Intensify

Guidelines Tie Diet and Exercise to GLP-1 Drug Success as India Launches Treatments

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

Weight Loss Drugs Reshape Food Industry and Consumer Habits

GLP-1 Drugs Show Promise Beyond Diabetes and Obesity but Raise Cost and Ethical Concerns

Elon Musk and RFK Jr. Clash Over Weight-Loss Drug Policies

Cost and Efficacy Concerns Arise for GLP-1 Weight Loss Drugs